In the anti-IL-6R antibody (tocilizumab; ACTEMRA®, Rhoch Inc., San Francisco, CA, USA) treatment group, the tumor growth was inhibited only in the SW480 xenografts. This evidence concerns the gene IL6R and neoplasm.